Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
We propose to improve the possibility of reaching skin resolution by identifying certain
markers or gene patterns that may predict patient response to certain psoriasis drugs ahead
of time, thus eliminating or reducing the trial-and-error approach often employed. The
ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to
a more personalized approach for psoriasis treatment.
To do this, we will be asking you to try two different already on the market FDA-approved
psoriasis drugs for 8 weeks at a time. We will be monitoring your skin for improvements as
well as taking blood and skin samples at least three times. We may also ask to take stool
samples and/or skin swabs.